Can you teach me about prostate carcinoma?

Prostate Carcinoma: A Comprehensive Overview

Epidemiology and Incidence

Prostate adenocarcinoma is the most common non-cutaneous malignancy in men, with approximately 288,300-299,000 new cases diagnosed annually in the United States, representing 29% of all male cancers. 1, 2

Current Incidence Patterns

• Annual incidence in the U.S. ranges from 97 to 173 cases per 100,000 men, varying significantly by race 3
• Worldwide, approximately 1.47 million new cases occur annually, with 396,792 deaths in 2022 2
• After declining 40% from 2007-2014, incidence has risen 3% annually since 2014, driven primarily by increased diagnoses of regional and metastatic disease 1, 3
• This recent upward trend correlates with reduced PSA screening following the 2012 USPSTF recommendation against routine screening 1, 3

Age Distribution

• More than 70% of cases occur in men older than 65 years, with median age at diagnosis of 67-71 years 3, 2
• Prostate cancer is rare before age 50, accounting for only 1% of all cases 4
• A 50-year-old man has a 42% lifetime chance of harboring histologic prostate cancer, 9.5% chance of clinically significant disease, and 2.9% chance of dying from the disease 3

Racial and Ethnic Disparities

Black men experience the highest burden of prostate cancer, with incidence rates 67-70% higher than White men and mortality rates 2-4 times greater than all other racial groups. 1, 3

• Black men: 173 cases per 100,000 annually 3
• White men: 97 cases per 100,000 annually 3
• Black men present with higher Gleason scores and more advanced pathological stage, though stage- and grade-adjusted mortality is comparable to White men 3
• American Indian/Alaska Native populations also have higher mortality than White individuals 1
• Men of Japanese or Chinese ancestry have very low mortality (2-20 deaths per 100,000), but immigrants to the U.S. show increased risk, indicating environmental and dietary factors 3

Risk Factors

Genetic and Familial Risk

Approximately 9% of prostate cancers are attributable to inherited predisposition, with more than 50% of overall risk linked to genetic factors. 1, 3, 2

• One first-degree relative with prostate cancer: 2.5-fold increased risk 3
• Two affected relatives: 5-fold increased risk 3
• Three affected relatives: 11-fold increased risk 3
• Early-onset prostate cancer (diagnosed before age 55): 42% may be inherited 3
• BRCA2 mutations confer 2-6 fold increased risk and are associated with more aggressive disease 3

Other Risk Factors

• Older age is the strongest non-genetic risk factor 2
• High-fat Western diet has been implicated in geographic variation 3
• Environmental factors play a significant role, as evidenced by immigrant studies 3

Pathology and Histology

More than 99% of prostate cancers are adenocarcinomas, typically arising in the peripheral zone of the prostate (70% of cases). 5

Gleason Grading System

• The Gleason score is the gold standard for determining tumor aggressiveness and prognosis 5
• Reported by pathologists along with extent of involvement of each biopsy core 3
• Prostate cancer is heterogeneous, with coexistence of tumor cells with different degrees of differentiation in the same tumor 5

Precursor Lesions

• High-grade prostatic intraepithelial neoplasia (PIN) is the precancerous lesion observed in most adenocarcinomas 5
• PIN is more frequent in African American men 3

Screening and Diagnosis

PSA Screening

The 2018 USPSTF updated recommendations support individualized, informed decision-making regarding PSA screening in men aged 55-69 years, representing a more balanced approach than the 2012 recommendations against routine screening. 1

• PSA levels 0-2 ng/mL: approximately 1% probability of prostate cancer 3
• PSA levels 4-10 ng/mL: consider free PSA measurement to refine cancer risk evaluation 3
• PSA testing rates increased after the USPSTF's 2017 draft statement was released 1

Diagnostic Approach

• Digital rectal examination (DRE) combined with PSA screening allows detection at earlier stages 1
• Transrectal ultrasound-guided biopsy is the standard diagnostic method 1
• Most common clinical stage is T1c: tumor identified by needle biopsy due to elevated PSA 6

Staging and Prognosis

TNM Staging System

The TNM staging system (sponsored by AJCC and UICC) is the predominant classification system, critically important for determining prognosis, guiding treatment decisions, and predicting mortality outcomes. 6

T Classification (Primary Tumor)

• T1: Clinically inapparent tumor not palpable or visible by imaging 6
  • T1a: Incidental finding in ≤5% of resected tissue 6
  • T1b: Incidental finding in >5% of resected tissue 6
  • T1c: Identified by needle biopsy due to elevated PSA 6
• T2: Tumor confined within prostate 6
• T3: Tumor extends through prostate capsule 6
  • T3a: Extraprostatic extension 6
  • T3b: Seminal vesicle involvement (only 25% remain biochemically progression-free at 10 years) 6
• T4: Tumor fixed or invades adjacent structures 6

N Classification (Regional Lymph Nodes)

• N0: No regional lymph node metastasis 6
• N1: Metastasis in regional lymph node(s) (pelvic nodes below bifurcation of common iliac arteries) 6
• Lymph nodes ≥1.5 cm in short axis are considered pathological and measurable 1

M Classification (Distant Metastasis)

• M0: No distant metastasis 6
• M1a: Nonregional lymph nodes 7
• M1b: Bone metastases (most common site, occurring in 84% of metastatic cases) 1, 7
• M1c: Other sites with or without bone disease (liver, lung, brain) 7

Clinical vs. Pathological Staging

• Clinical staging (cTNM) is based on examination, imaging, and biopsy before treatment 6
• Pathological staging (pTNM) is based on surgical specimens after radical prostatectomy and is more predictive of prognosis 6

Survival Rates

• Approximately 75% of patients present with localized disease, associated with nearly 100% 5-year survival 2
• Regional lymph node involvement (14% at presentation): intermediate prognosis 2
• Distant metastases (10% at presentation): 37% 5-year survival 2
• Overall 5-year relative survival for all stages combined: 97% 1

Patterns of Dissemination

Prostate cancer disseminates through three primary pathways: local extension through the prostatic capsule, lymphatic spread to regional and pelvic lymph nodes, and hematogenous spread predominantly to bone. 7

Metastatic Sites

• Bone: 84% of metastatic cases 1, 7
• Distant lymph nodes: 10.6% of cases 7
• Other sites (liver, chest, brain): less common 7

Prognostic Indicators for Metastatic Spread

• PSA doubling time (PSADT) <6 months strongly suggests metastatic dissemination rather than local recurrence 7
• Hematogenous dissemination occurs predominantly after invasion of the muscularis propria 7

Treatment Approaches by Stage

Localized Disease (T1-T2, N0, M0)

For organ-confined disease, treatment options include active surveillance, radical prostatectomy, external beam radiation therapy, or brachytherapy, with selection based on risk stratification incorporating life expectancy, Gleason score, tumor size, and PSA level. 1, 2

Active Surveillance

• Appropriate for approximately one-third of patients with localized prostate cancer 2
• Involves serial PSA measurements, prostate biopsies, or MRI monitoring 2
• Treatment initiated if Gleason score or tumor stage increases 2
• Best suited for low-risk disease (T1-2a, Gleason <6, PSA <10 ng/mL) 3

Radical Prostatectomy

• Pelvic lymph node dissection (PLND) recommended if predicted probability of lymph node metastasis ≥2% 1
• Advantages include complete pathological staging 1
• Complications and prognostic factors must be discussed 1

Radiation Therapy

• External beam radiation therapy (EBRT) ± androgen deprivation therapy (ADT) for 4-6 months 1
• May be combined with brachytherapy 1
• Brachytherapy alone is an option for favorable intermediate-risk disease 1

Intermediate-Risk Disease

For patients with intermediate-risk disease and life expectancy ≥10 years, EBRT with 4-6 months of ADT ± brachytherapy, or brachytherapy alone are recommended initial therapies. 1

• Patients with favorable intermediate-risk features (predominant Gleason grade 3, <50% positive biopsy cores, no more than one NCCN intermediate risk factor) may be considered for less intensive treatment 1

Locally Advanced Disease (T3-T4)

Locally advanced disease requires multimodal approaches, with androgen suppression before, during, or after external beam radiotherapy significantly improving local control, reducing disease progression, and improving overall survival. 6

Metastatic Disease

For newly diagnosed metastatic prostate cancer, first-line therapy combines androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (such as abiraterone or darolutamide), which significantly improves survival compared to ADT alone. 2

Androgen Deprivation Therapy

• Medical castration with gonadotropin-releasing hormone (GnRH) agonists is the primary treatment 1, 2
• Bilateral orchiectomy is an alternative 1
• LHRH analogs should be accompanied by antiandrogen for 4 weeks 6

Combined Therapy

• Addition of abiraterone improved median overall survival from 36.5 months to 53.3 months (HR 0.66,95% CI 0.56-0.78) compared to medical castration alone 2
• Nonsteroidal antiandrogen in addition to castrate therapy provides small survival benefit for patients willing to accept increased toxicity 1
• Steroidal antiandrogens should not be offered as monotherapy 1

Chemotherapy

• Docetaxel may be considered, especially for patients with more extensive disease 2
• Reserved for appropriate patients based on performance status and disease burden 2

Mortality Trends

Mortality rates have declined substantially over the past three decades, from approximately 40,000 deaths per year in the early 1990s to an estimated 34,700-35,250 deaths in 2023-2024. 1, 2

• In Minnesota, mortality decreased from 34 per 100,000 males in 1990 to 19.4 per 100,000 in 1997 1
• Age-adjusted death rates declined 52% from 1993 to 2017 1
• Recent years show more stable rates with 0.6% annual decrease from 2013-2020 1
• This low death rate is threatened by rising incidence and diagnosis of advanced disease 1

Stage Migration and Modern Trends

Contemporary practice has seen significant stage migration, with decreased rates of positive surgical margins, locally advanced cancers, and node-positive cancers, accompanied by increased detection of clinically localized cancers. 1

• This stage migration is likely related to PSA screening, though the exact contribution is debatable 1
• Better use of PSA for early detection coupled with imaging and biomarkers should decrease overdetection 1
• PSMA PET/CT has significantly superior accuracy to conventional imaging for detecting visceral metastases 7

Key Clinical Considerations

Pathologic Confirmation

• Recommended when feasible, particularly for isolated lesions where treatment decisions may be altered 7

Risk Stratification Tools

• Partin tables incorporate TNM staging to predict extraprostatic extension, seminal vesicle involvement, and lymph node involvement 6
• Multiple risk prediction models are available for clinical decision-making 1

Staging Workup

• Routine staging should include complete blood count, alkaline phosphatase, creatinine, and serum total PSA 6
• Digital rectal examination, transrectal ultrasound, chest X-ray, and bone scintigraphy are recommended 6
• Bone scintigraphy indicated if bone metastases suspected clinically, tumor poorly differentiated, or PSA >10 mg/L 6

Treatment Decision-Making

• Full discussion between practitioner and patient should occur to determine optimal therapy 1
• Treatment decisions should incorporate adverse events and comorbidities 2
• Despite definitive therapy, 2-56% of men with localized disease develop distant metastases, depending on tumor risk factors 2